Pyxis Oncology (PYXS)
(Real Time Quote from BATS)
$3.50 USD
+0.07 (2.04%)
Updated Aug 16, 2024 11:46 AM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
PYXS 3.50 +0.07(2.04%)
Will PYXS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for PYXS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PYXS
Pyxis Oncology, Inc. (PYXS) Reports Q1 Loss, Tops Revenue Estimates
Does Pyxis Oncology (PYXS) Have the Potential to Rally 61.29% as Wall Street Analysts Expect?
PYXS: What are Zacks experts saying now?
Zacks Private Portfolio Services
All You Need to Know About Pyxis Oncology (PYXS) Rating Upgrade to Buy
Down -15.56% in 4 Weeks, Here's Why You Should You Buy the Dip in Pyxis Oncology, Inc. (PYXS)
Pyxis Oncology, Inc. (PYXS) Upgraded to Strong Buy: What Does It Mean for the Stock?
Other News for PYXS
Analysts Offer Insights on Healthcare Companies: Gryphon Digital Mining (GRYP) and Pyxis Oncology (PYXS)
Buy Rating Affirmed for Pyxis Oncology Amid Strong Financials and Promising Clinical Trials
Pyxis Oncology GAAP EPS of -$0.29
Pyxis Oncology Provides Corporate Update and Reports Financial Results for Second Quarter 2024
PYXS Stock Earnings: Pyxis Oncology Misses EPS for Q2 2024